• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
147803 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
6 S& t3 q7 Y  v- k( B
, A; f3 r, Y% a0 H$ k  ?- y* `3 C# M" G
Sub-category:
1 b. [! D3 Z- Z3 l6 H' Z$ m- g' eMolecular Targets 7 c7 w# N: o! Q

* L& B" B* o5 |
6 v& w( D5 Z! M0 s, QCategory:
7 `; b2 G" D7 X1 Y+ t6 hTumor Biology
4 [, r2 h0 g  g# ]' x/ C  B+ n1 E6 B/ z" l1 J
3 {& q. n, o4 p
Meeting:4 b0 U! l8 O" y1 _1 r7 E
2011 ASCO Annual Meeting
) b/ g1 ~4 u3 ^$ ~( r7 J* Z8 x$ X: |0 G" V

- }; i- T& `+ i+ b" hSession Type and Session Title:5 }* ~  j; [: g4 B$ f( `" \
Poster Discussion Session, Tumor Biology " B( T( Q: c6 {) V0 e6 [9 w

$ @8 V/ |  B0 K$ v  M$ J
2 o. j$ Q0 C# V6 O' C0 lAbstract No:
+ G& o" V2 e5 j6 H1 f; a10517
1 Z7 y* I7 X4 k! f$ E5 m% `- ~7 \- `" w! @" U+ F+ k# |- G1 u

- v( E& G$ q- O  e+ LCitation:
# n! b5 c" C  z4 o$ QJ Clin Oncol 29: 2011 (suppl; abstr 10517)
. e8 `& u3 m) M6 c0 N# w
7 [9 @$ D. V( X. D8 M& Q1 L  @/ n
; j& ~% T1 w! t3 @$ e( n* dAuthor(s):! a! m" t' P9 J( L/ I) r% W
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China # ^6 n$ `1 n- u/ Y
. ^7 C8 B( V* R' `7 X9 D
) t+ Q' p. |; v" p  d. ]
/ H3 q  R" w& k# r+ `, `
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
# {) F. _  r; e1 b
0 X$ s# R& r7 x9 L& f. YAbstract Disclosures! S' S. G9 b- g2 J( E+ X7 J
3 @0 ~& a. M' d/ K& P* ^# K* u" T
Abstract:4 k. {3 X0 K: Q8 v$ H5 Q
) h3 T% `: t" X8 Z6 {
8 _! N- u1 \( U
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
1 F! j& T' ?6 m2 A. y7 I; b/ R$ u
6 Y* u$ h1 D% c& c5 D" ]
7 n8 Q% {7 i. M* }; H
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 - I. q0 r% T: _/ V! W7 A
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

( r+ q3 j& F; G- U化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ( \! c; E2 p: {" J" Y6 n# n
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。* P0 Z) `5 b+ i0 R+ _
ALK一个指标医院要900多 ...
( m. y' F8 j! b8 U4 _
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?7 @$ A7 x) |7 V
3 M: j. Z- _$ t0 I8 ?
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表